论文部分内容阅读
对数百种合成化合物筛选的结果表明,日本化药公司新开发的MN-1695抗溃疡作用最强,且毒性低。其药理学特点是低用量便可对各种急、慢性溃疡模型产生抗溃疡作用,且具有胃粘膜防御作用和可使胃粘膜血流轻度上升的作用。 MN-1695第三期试验对胃溃疡治疗效果和安全性进行了研究。对象21例,药物每片含M~N-1695 2mg,分别采用二种给药方法:①每日一次早晨给药4mg;②每日4mg分早、晚二次给药。用药时间,原则上8周。
The results of screening of hundreds of synthetic compounds show that MNP-1695 newly developed by Nippon Kayaku Co., Ltd. has the strongest anti-ulcer effect and low toxicity. Its pharmacological characteristics of low dosage can be a variety of acute and chronic ulcer models have antiulcer effects, and has a gastric mucosal defensive role and gastric mucosal blood flow can slightly increase the role. MN-1695 Phase III trial of gastric ulcer treatment efficacy and safety were studied. Subjects in 21 cases, each drug containing M ~ N-1695 2mg, were administered by two methods: ① once daily administration of 4mg; ② daily 4mg points early and late administration. Medication time, in principle, 8 weeks.